Overview

Study to Prevent Acute Kidney Injury After Cardiac Surgery Involving Cardiopulmonary Bypass

Status:
Active, not recruiting
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to assess the safety and efficacy of ANG-3777 in preventing AKI compared to placebo when administered to patients at risk for developing acute kidney injury (AKI) following cardiac surgical procedures involving cardiopulmonary bypass (CPB).
Phase:
Phase 2
Details
Lead Sponsor:
Angion Biomedica Corp
Collaborators:
Clinical Accelerator
CTI Clinical Trial and Consulting Services
Everest Clinical Research
Treatments:
Mitogens